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INTRODUCTION
Neuroendocrine carcinomas are malignant tumors that show
histopathological and immunohistochemical evidence of neu-
roendocrine differentiation. Neuroendocrine carcinomas can
develop at many sites of the body, but primary neuroendocrine
carcinoma of the breast is very rare (1). There are different his-
tologic subtypes of neuroendocrine carcinomas of the breast
that have been reported in the literature (1-4). In 2003, the
World Health Organization (WHO) recommended classifi-
cation of these tumors into three histologic types: solid, small-
cell, and large-cell neuroendocrine carcinoma (5). There are
some reports of neuroendocrine carcinoma of the breast in the
pathology literature (2, 3), but there are few reports that describe
the imaging features (6, 9) and most of them are about small-
cell carcinomas. To our knowledge, the radiologic appearance
of primary large-cell neuroendocrine carcinoma (LCNC) of
the breast has not been described previously. In this case report,
we present the radiologic and pathologic findings of prima-
ry LCNC of the breast in a 27-yr-old woman.
CASE REPORT
A 27-yr-old woman presented with a palpable mass in her
left breast. The mass was first noticed one year previously and
it had grown substantially. She had no remarkable past med-
ical history, no family history of breast, colon, or ovarian can-
cer, and was not on any medications. On physical examina-
tion, a soft, movable mass was palpated in the left breast. The
lesion was located at the three o’clock position of the left breast
4 cm from the nipple. There was no axillary lymphadenopa-
thy, skin retraction, or abnormal nipple discharge. Mammog-
raphy showed a relatively well-demarcated, lobular shaped
mass in the mid-outer portion of the left breast (Fig. 1). Breast
ultrasonography (US) revealed a circumscribed oval, gently
lobulated, heterogeneous, low-echoic mass measuring about
3.2×1.3 cm in size in the left breast (Fig. 2). The lesion was
thought to be low suggestion of malignancy, BI-RADS cate-
gory 4A. An ultrasound-guided 14G core needle biopsy was
performed for the mass. On a chest CT scan, the lesion app-
eared as a well-defined, highly-enhancing mass in the left
breast (Fig. 3). In the right upper lung, there was pulmonary
tuberculosis lesion, but we could not find any lesions sug-
gestive of primary lung cancer. Abdominal ultrasonography,
whole body bone scan and PET CT scan were performed for
preoperative metastasis work-up and no distant metastasis
was found. She underwent breast-conserving surgery and
left axillary lymph node dissection. On microscopic examina-
tions (Fig. 4), small nests of large tumor cells with faintly gran-
ular cytoplasm were present and separated by dense colla-
gen bundles. An immunohistochemical panel (Fig. 5) was
Some breast neoplasms are classified as primary neuroendocrine carcinomas
because they are positive for neuroendocrine markers. Although neuroendocrine
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docrine carcinoma of the breast can only be made if nonmammary sites are confi-
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on the mass, and primary LCNC was confirmed by histopathologic examination.
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performed, and the tumor was found to be positive for neu-
roendocrine markers (chromogranins, synaptophysin, and
neuron-specific enolase [NSE]). These pathologic findings
were compatible with primary LCNC.
She underwent adjuvant chemotherapy and radiation ther-
apy. At 18 months post-operation, there was no evidence of
local recurrence or distant metastasis.
DISCUSSION
More than 97% of neuroendocrine tumors occur in the
gastrointerstinal or respiratory system, and primary neu-
roendocrine carcinoma of the breast is very rare. In a series
of 1,845 histopathologically-proven breast cancer, the inci-
dence was about 0.27% (6).
The diagnosis of primary neuroendocrine carcinoma of the
Fig. 1. Mammography
showed a relatively
well-demarcated, lob-
ular shaped mass in
the mid-outer portion
of the left breast.
Fig. 2. Breast US revealed an oval shaped, micro-lobulated, het-
erogeneous low-echoic mass, measuring about 3.2×1.3 cm in
size, in the left breast.
Fig. 3. Chest CT scan showed a well-defined, highly-enhancing
mass in the left breast.
Fig. 5. The tumor stained positive for chromogranin A (magnifi-
cation ×200) and also expressed neuron-specific enolase and
synaptophysin (not shown).
Fig. 4. Photomicrograph of a histopathologic specimen showed
small nests of large tumor cells with faintly granular cytoplasm sep-
arated by dense collagen bundles (Hematoxylin-eosin, magnifi-
cation ×200). 1120 J.W. Kim, O.H. Woo, K.R. Cho, et al.
breast can only be made if nonmammary sites are confident-
ly excluded or if an in situ component can be found (9). There
are different histologic subtypes of neuroendocrine carcino-
mas of the breast reported in the literature (2-4). Papotti et
al. divided neuroendocrine carcinomas into seven histologi-
cal types (A-G) (2). Sapino et al. described five different his-
tological types: solid cohesive, alveolar, small cell, solid pap-
illary, and cellular mucinous (3). In 2003, the World Health
Organization (WHO) recommended differentiation of these
tumors into three histologic types: solid, small-cell, and large-
cell neuroendocrine carcinoma (5). There are some features
that favor neuroendocrine differentiated carcinoma of the breast
and morphologic features should be confirmed immunochem-
ically or by positivity for neuroendocrine markers (3). NSE,
chromogranin, and synaptophysin are widely accepted as
neuroendocrine markers, though NSE is relatively non-spe-
cific (4). In our case, the three aforementioned neuroendocrine
markers were all positive. 
LCNC, one of the subtypes of the 2003 WHO classifica-
tion of neuroendocrine tumors, shares common features of
the neuroendocrine-differentiated tumor described above
and also shows more specific cytologic features: large cell size,
polygonal shape, low nuclear-cytoplasmic ratio, finely granu-
lar eosinophilic cytoplasm, occasionally prominent nucleoli,
peripheral palisading, mitosis, and necrosis (8).
In a clinical setting, neuroendocrine carcinomas usually
occur in women around the 7th decade; most patients in the
previously reported cases were between 40 and 70 yr old (2,
4-6, 9). Our patient was a 27-yr old woman without risk fac-
tors of breast cancer and presented with a painful breast mass
that had appeared about one year prior. The mass was soft
and movable on physical examination. It is an uncommon
presentation of breast cancer, considering the patient’s age
and clinical findings. The prognosis of neuroendocrine-dif-
ferentiated carcinoma is a subject to debate, probably due to
different growth patterns of the subtypes and the low num-
ber of cases. In some recent literature, primary neuroendocrine
carcinomas of the non-small cell type have shown satisfacto-
ry prognosis with adequate surgical excision and adjuvant
chemotherapy (5, 10).
Previously noted mammographic findings of neuroendocrine
carcionoma included high-density round masses with spicu-
lated or lobulated margin (6, 9). Our findings are not signif-
icantly different. US findings of our patient were those of
gently lobulated, heterogenous, low-echoic mass. In one series
of five neuroendocrine carcinomas, most of the lesions demon-
strated homogeneous low-echoic masses, though the WHO
classification was not used and all of the lesions were of the
solid and papillary subtypes (6). US findings in small-cell
carcinoma reported by Mariscal et al. was of a solid, homo-
geneous, low-echoic mass with a partially ill-defined margin
and mild posterior acoustic enhancement (9). In our case,
CT findings are also presented. A chest CT scan was per-
formed as part of a metastastic work-up as well as for evalu-
ation of pulmonary tuberculosis. The lesion appeared as a
well-defined, highly-enhancing mass in the left breast.
In summary, we presented imaging findings of a LCNC of
the breast. This is the first report describing imaging features
of large-cell type neuroendocrine carcinoma and presenting
the CT findings of a neuroendocrine-differentiated carcino-
ma in Korea. This is a rare entity, and description of more
cases is necessary to determine the radiologic and clinical
features of LCNC.
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